Ladies and gentlemen, good day and welcome to NOCIL Limited Q2 FY 2027 earnings conference call. This conference call may contain forward-looking statements about the company, which are based on beliefs, opinions, and expectations of the company as on the date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. As a reminder, all participants' line will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. V. S. Anand, Managing Director from NOCIL Limited. Thank you, and over to you, sir.
Thank you, Vikram. Thank you and good morning to everyone. I'd like to start by expressing my appreciation for your presence today. Joining me are Mr. P. Srinivasan, our Chief Financial Officer, and our Investor Relations Advisors from SGA. I hope you have all received our investor presentation. If not, it's available in both the stock exchanges and on our company's website. When I look at the first half of this year, I believe the important point is that we have continued to make progress in a challenging business environment. We have had to navigate global uncertainty, supply-side disruptions, and competitive pressures. At the same time, we have continued to invest in strengthening NOCIL for the long term. Let me begin with a brief overview of our performance. We concluded the H1 FY 2027 with revenue of INR 830 crores, a growth of 26% over the corresponding period last year.
Volumes grew by 3%, supported by sustained demand across our key end markets. Domestic volumes registered single-digit growth, aided by improved demand following the implementation of GST 2.0. Export volumes also recorded single-digit growth, reflecting continued traction across international markets and the conversion of customer engagements into business opportunities. For quarter two, revenue from operations stood at INR 427 crores, registering a YoY growth of 33% and sequential growth of 6%. This was primarily driven by an increase in the average selling price. However, volumes declined by 3% YoY and 7% sequentially due to temporary supply-side constraints and logistical challenges arising from the geopolitical situation. While these disruptions impacted our quarterly volumes, our customer engagement and underlying demand remain healthy. We have addressed the supply-side constraints, and we expect the affected volumes to recover in the second half.
The quarter's performance also reflects the continued competitive pressures in the market, including the impact of import dumping. Our focus remains on balancing price and volumes while protecting our competitiveness. Let me now briefly touch upon the industry environment. Domestic tire demand continued to benefit from the consumption tailwinds following GST 2.0. At the same time, the industry faced higher raw material costs, with crude oil prices rising during the quarter amid geopolitical tensions. This has had a bearing on input costs across the value chain. Looking ahead, a weaker monsoon and inflationary pressures could create some near-term demand headwinds. However, the underlying industry fundamentals remain supportive, driven by healthy replacement demand, growth in OEM volumes, and favorable long-term growth drivers. We therefore remain positive on the industry's long-term prospects while recognizing that the near-term operating environment continues to be challenging.
Coming back to NOCIL, I would like to highlight the progress we are making on our investments. Our brownfield TDQ expansion at Dahej is progressing towards customer approvals, which we expect over the coming months. Work on our integrated specialty rubber chemicals project is also progressing as planned. These investments are important steps in strengthening our product portfolio and manufacturing capabilities and in positioning NOCIL for future growth. Looking ahead, we remain focused on deepening customer relationships, expanding our presence in domestic and export markets, and pursuing new product opportunities. Coming to our financial year 2027 outlook, as highlighted during our last earnings call, we had indicated a revenue range of INR 1,400-INR 1,600 crores. Given our H1 performance and the current momentum, we remain confident of closing FY 2027 towards the upper end of this range, with EBITDA margins of around 10%.
While the operating environment remains uncertain, our priorities are clear. We will continue to focus on our customers, operational excellence, disciplined investments, and financial discipline while building the capabilities required for sustainable long-term growth. As part of our efforts to build a more cyclically resilient business and utilization of our cash chest, we have been actively exploring opportunities for inorganic growth in the chemical space, and we will keep you posted as and when there is any development in that space. With this, I now invite Mr. P. Srinivasan to provide an overview of our financial performance.
Thank you, Mr. Anand, and good morning to everyone. Let's run through the Q2 and H1 FY 2027 consolidated financial highlights. Sales volume: Volumes for Q2 FY 2027 was 135, taking a base of 100 as Q1 FY 2020. Revenue: Net revenue from operation for Q2 FY 2027 stood at INR 427 crores, registering a growth of 33% on YoY basis and 6% on QoQ basis. For H1 FY 2027, net revenue from operations stood at INR 830 crores, registering a growth of 36% on YoY basis. EBITDA: EBITDA for Q2 FY 2027 stood at INR 36 crores, registering a growth of 61% on YoY basis, while witnessing a degrowth of 20% on QoQ basis, with margins standing at 8.4%. For H1 FY 2027, EBITDA stood at INR 81 crores, registering a growth of 54% on YoY basis, while margins standing at 9.8%.
Profit Before Tax, PBT, for Q2 FY 2027 stood at INR 28 crores, registering a growth of 52% on YoY basis, while witnessing a degrowth of 24% on QoQ basis. For H1 FY 2027, PBT stood at INR 65 crores, registering a growth of 57% on YoY basis. Profit After Tax, PAT, for Q2 FY 2027 stood at INR 24 crores, registering a growth of 98% on YoY basis, while witnessing a degrowth of 13% on QoQ basis. For H1 FY 2027, PAT stood at INR 52 crores, registered a growth of 76% on YoY basis. With this, we would like to open the floor for question- and- answers.
Thank you very much. We will now begin with the question- and- answer session. Anyone who wish to ask a question may press star and one on their touch-tone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is from the line of Nirav Jimudia from Anvil Wealth Management Private Limited. Please go ahead.
Yeah, good morning, sir. Few questions. Sir, first on the volume growth side, like last quarter you mentioned that for FY 2027, the top line assumption we have taken close to around 10% volume growth. Just going by that number, let's say for achieving this sort of numbers for FY 2027, for H2 FY 2027, on an indexation basis, we need to do a volume at a rate of around 165. How confident are we in terms of achieving these numbers for second half? If you can give some qualitative understanding about the volume growth from where this volume growth could accrue to us, that would be very helpful.
Yeah, thank you, Nirav. Yes, you are right about the indication we had given on the volume growth, and we are quite positive that we will be able to still stay in the 8%-10% growth in terms of volumes. I am positive that from the index point that you touched, I would say at least in the 160 range should be there, 160- 165.
Got it.
Again, coming back to the additional point about the quality of the growth, it is going to come from a combination of both domestic as well as the international markets. That is why we are quite positive. Yeah.
Perfect. Sir, just going by that indexation numbers, let us say if we have been able to achieve this number for second half, this automatically ensures that, let us say for FY 2028, this also ensures 10% volume growth. Is this a right assumption to work with even for FY 2028?
Yeah, I would say that is a fair assumption to take. Yeah.
Correct. Sir, second question is, like on the gross margin side and on the conversion cost side, let us say just going by the simple maths, like if we have seen, like what we have seen for H1, our gross margins run rate is close to around INR 700 crores, and our conversion cost run rate is close to around INR 520 crores. If we just subtract this, our EBITDA should be closer to around INR 180 crores.
Here, I am not taking the benefits of any operating leverage which could accrue to us in terms of the higher volumes which we are expecting for second half. In your opening remarks, you mentioned that we have been confident enough in terms of achieving INR 1,600 crores of top line with 10% margins. Aren't we conservative enough in terms of giving this guidance since the metrics are showing on a slightly upper end?
Yeah, while you are right, there is a bit of conservatism given the fact that, typically, from one quarter to the other, the environment is also evolving. There is a bit of conservatism, but we will strive to really achieve more. That is for sure. Yeah.
Perfect. Last question from my side. In terms of first quarter, we had issues with respect to power. Second quarter, we had an issue with respect to the shipping issues or the supply constraints and the other factors. Where are we currently in terms of addressing these factors, and can we see the benefit of the captive power boilers which we have put up accruing to us with respect to the higher volumes which we are expecting for second half? Thank you.
Yes. That should start kicking in the second half. Coming to the point about some of the challenges we had, they have been addressed. As we speak, they are addressed, and we expect that the volume should start picking up from a production point of view too. Also the point about the turbines and all that, full utilization of it will come into play as we increase the volumes in the coming months. Yeah.
Perfect, sir. Thank you so much and wish you all the best.
Thank you. Thanks.
Thank you. The next question is from the line of Aditya Khetan from SMIFS Institutional Equities. Please go ahead.
Thank you, sir, for the opportunity. Sir, just a couple of questions. Sir, onto the volume guidance, like you mentioned to the earlier participant. When we look, today's environment, oil prices are at record high, volatility is there, geopolitical uncertainties are still lingering around. Even tire volumes growth has been moderated by some of the good credit rating agencies from 8%-8. 4%, 8. 5%. What is that optimism, which is driving us for this stronger volume growth in H2 versus H1? First. Sir, second question, like when we look also at the conversion cost over the last few quarters, like we were witnessing some lower power cost control on freight. But that benefit is also now going away. We are witnessing some INR 10- INR 20 per kg jump in conversion cost also.
What is the outlook over there? Will this come down as and when freight prices normalize, or like this would continue to stay?
Yeah, so on the volume front, like you rightly said, there has been a bit of a moderation in terms of also the market expectation. But what we have also considered, we have factored that in terms of the volumes, but we also see that quite a few opportunities in the international markets are also fructifying. These things will also kind of contribute to mitigate some of those effects. But there is quite positive that 8%-10% will come from a combination of both these efforts here. Coming back to the conversion cost, I'll just begin, and then maybe Srini can also please come in. Yeah, so it's a combination of the fact that we have had significant increase in fuel costs, which have played out a role, both in terms of coal as well as gas.
Our freight costs, not only domestic, but also sea freight, you know the situation is quite kind of spiraled to quite high levels. These are also playing out. Srini, anything else that you would like to add here?
I think one of the things which we saw in this quarter is, I mean, this half year basically, they said the utilities cost has significantly increased, both the coal, gas rates, et cetera. So, that has an impact on the conversion cost, direct relation to that, as also sea freight. Also, since we had some supply-side challenges, so we had some leveraging, all those leveraging benefit which we normally should have, that didn't accrue. So, probably in second half, we'll get all those things coming in.
Got it. Sir, you mentioned like the international volumes will see an uptake. So, largely, international volumes also include a portion of the specialized rubber chemicals also. So, how will that move up? So, will that also move up, or like that would remain flat only?
It would be in similar ratios. I don't see any significant jump in that, Aditya.
Got it. Okay. Sir, my next question is onto the anti-dumping duty side. Sir, recently, we had also filed for anti-dumping duty on 4-ADPA. I suppose, sir, if duty is imposed, that would correct the value chain of PX13 also. That's a good move. Sir, suppose if the duty is imposed and also factoring the sulphenamides duty, if suppose on 4-ADPA, what would be the additional quantum of percentage margins which NOCIL can additionally get? Just a ballpark number I'm asking. Also, a range would help, sir, on that side. Just a range number also if you can give.
One is on 4-ADPA, I would like to clarify, it's an intermediate or it's a precursor to Pilflex 13. Pilflex 13 anti-dumping duty recommendation unfortunately could not be notified or did not get accepted by the central government. Even if you have a duty protection, what will happen is, indirectly, it may make the other domestic producers, if it gets notified, their cost of production of Pilflex 13 will go up because there is an anti-dumping duty on 4-ADPA. But it may need not result in a higher price for Pilflex 13 because the import is still outside anti-dumping zone. What it may give, if at all if it happens, we don't know what will happen eventually after three months. It all depends to be seen what is going to be the final outcome.
But assuming there is a situation, there is an anti-dumping duty gets notified, probably, we may get the other domestic players will have some difficulty in production or they have to produce at a higher cost. All three will be competing with the imports. That is what we are looking at it. It remains to be seen at what price and what are the effects of it in the marketplace. That's on one point. Secondly, on the sulphenamides thing, it's not comparable in the sense because today the import data is just not available. We are unable to really quantify what is the exact benefit. We do factor in our pricing decisions some quantum of it. But how much the imports are undercutting, what are they pricing, none of us are aware of information to that.
Okay. Sir, just one last question, if you may allow. Sir, have you witnessed any sort of new capacity additions outlined by Chinese players, which could materially see sort of further higher competition from imports? Any sort of new capacity additions like in the global pipeline you have witnessed?
Nothing in the last few months apart from those ones that were already announced or getting on stream earlier. Yeah.
Got it, sir. Thank you, sir.
Thank you. A reminder to all the participants who wish to ask a question, you may press star and one now. The next question is from the line of Nitesh Dhoot from Anand Rathi Institutional Equities. Please go ahead.
Yeah. Good afternoon, team. Thank you for the opportunity. My first question is on the realizations, which I see is up by about 36% year-on-year. Can you give some color on how much of this increase also comes in from the ADD on CBS and NS, and how much is from the passing of the higher cost there? Is there any element of the ADD benefit at all? This is what I'm trying to understand.
It's not significant of that because the ADD is only on sulphenamides, so it's not significant. Some portion is there, but I think we cannot quantify the exact number.
Okay. No, because there's a INR 100 increase in realizations, and when we look at the increase in the EBITDA spread in the last couple of quarters, it's hardly INR 13. If there is any element of ADD, then it means that the rest of the part, I mean, structurally, the steady-state margins without ADD is becoming even weaker.
If I may come in, basically you have to look at two parts. If you see our annual report, 60% of our business is antioxidants. What we are talking about ADD sulphenamides, which is a small portion, it is not as high as 60%. That's number one. Whereas what we are seeing in the price increase is a reflection of cost increase also. That is factored in the delta is increased. What I think one of the participant had raised a question on that value addition, that shift has happened during this year. Basically the run rate has improved as compared to the previous years. That being the case, I think that includes a portion of the delta over the price and the cost, as well as some element of ADD. We cannot quantify the exact quantum at this stage.
Okay, sir. On the inventory part of it, what I see is that there is about INR 57 crore of inventory build that has flowed through the first half. Now, I mean, if the input prices, I mean, I understand that this would have been at a higher cost structure, right? So, if the input prices were to fall, what is the risk of reversal on that side?
First of all, we normally evaluate our working capital situation based on as a percentage of sales. In March 2025 or thereabout, we were about 30%+ or 32%+ . Now we have brought it down to around 25%. That is one thing we have made an effort to improve the working capital cycle. Secondly, as it stands today, because inventory is a rolling thing, it is maximum there for maybe next 40 days or next 60 days thereabout. As of this date, there is no significant effect in the next quarter.
Also to kind of further add to what Srini said, I think the key is also kind of managing inventory to an extent that you are not speculating too much and caught in a situation where, like what happened also, I think from the first quarter to second quarter, there was a bit of a drop in prices before it again went back up. So, we will have to be very aware of that situation and really plan very, very intricately. That is what we are doing to ensure that we have the optimum inventory for production and supply reliability. Yeah.
Yeah, no, I mean, rightly because the way we look at is that we have a tall task on the volume growth side for the second half, almost 16% growth is what we have to deliver. And if there is a reversal on the inventory side, I think we might end up missing our EBITDA guidances for sure in that case. So, that is why I just wanted to clarify. Sure. And lastly, sir, on the TDQ plant, your presentation says that it is delivered ahead of schedule, but it does not appear to have been capitalized. So, when will it be capitalized and how much increase in depreciation we see, and what return does it earn without the anti-dumping duty protection now?
Yeah. So, two things. The capitalization is we are waiting for the customer approvals. Some TACs and some customer approvals are pending. Once we receive that, we will be capitalizing it hopefully in this quarter, Q3. The annual depreciation charge, which is typically on a INR 120 crores, may be about INR 1 crore a month or INR 3 crores per quarter.
Understood. So, sir, thank you so much for answering the questions. Wish you the best for the coming quarters.
Thank you, Nitesh.
Thank you. Participants who wish to ask a question may press star and one at this time. The next question is from the line of Ravi Mehta from One Up. Please go ahead.
Yeah. Hi. Thanks for this call. Just one clarification. When I do a math of absolute gross profits that you make per ton, that is kind of holding on for last two quarters. In Q1, we have been told that there was some inventory benefit. In Q2, is it because of the ADD helping you to still maintain that if there was no inventory benefit? That is how I am trying to read it.
Your voice was a bit garbled sometimes.
Is it better now? Is it better now?
It was better towards the end, but again, now it is a bit garbled. Just go ahead. Now we can understand what you are trying to say. Just go ahead.
I'm just saying, the gross profit per ton seems to be pretty firm and sustained for last Q1 and Q2. In Q1, we were given to understand there were some inventory benefits, which may not be there in Q2. Is it the anti-dumping duty on sulphenamides coming in which is helping you to still maintain that gross profit on a tonnage basis? Is this a sustainable number, given there are no inventory anomalies of gains or losses?
Ravi, I think there are two things. One is, as I said to the previous participant, that sulphenamide is not a significant portion of our overall basket. 60% is antioxidants. Whereas when we are looking at the gross margin, it includes in the complete basket mix. Having said that, there is some portion of anti-dumping duty in Q2. We are not denying that. That is definitely there. But I think not everything is towards anti-dumping. Secondly, the way things have evolved in the first six months, I think the market is, at least the conditions, the market environment has changed better as compared to, relatively as compared to the previous year. I think if you look at your run rate of INR 700 crores, currently we are operating as compared to last year, we were probably operating at INR 1,520 or INR 525 crores per annum.
In that sense, there is a significant improvement. Not everything can be attributed to legacy cost or anti-dumping. Some portion of market conditions also changed.
It is yet to You got only benefit for past part of the quarter, and we can still see some benefit for the full quarter in Q3?
Yeah, so it was part of it for the last quarter.
Okay, cool. Thanks. Thank you so much.
Thank you. The next question is from the line of Pavan from Nayan M. Vala Securities. Please go ahead.
Hello. Thank you for the opportunity. Am I audible?
Yes, you are. Please go ahead.
Can you confirm your revenue expectations for this year?
We have given an indication of INR 1,400-INR 1,600, and like I said in my initial speech, we see it to the upper side of it, yeah.
On upper side of INR 1,600, if I do a calculation for the H2, where we expect a 16% volume growth, are we expecting a close to 20%-22% realization degrowth for H2 from H1?
As this. I think what Mr. Anand's guidance was, we are looking at an index of 160 and above in terms of index in volume terms. Based on the current pricing, yes, you can see a possibility of exceeding the numbers, but it all depends on how the volume tapers out. Today, based on the current pricing, yes, you can see it even exceeding that INR 1,600 also. But today, we are on a conservative side because we don't know what is the fourth quarter going to be.
Based on the current prices, are the prices above the H1 realization?
Yes, there is a marginal uptick, at least that we see for quarter three . Yeah.
One last question. What is our CapEx expectation for FY 2027 and FY 2028?
2027 and 2028 CapEx. We have this INR 130 crores which was sanctioned by the board. That spend is there. There are some other maintenance CapEx also is there. These are the two main things. Rest all is nothing that is forcing.
It is for FY 2027, right?
FY 2027 and FY 2028, both together. INR 130 crores, we have spent something. We are going to spend something over H2 and next year's H1. Also some routine CapEx, which is always there, maintenance CapEx come in. That also comes in. It is not significant, but it will come.
Okay, you mean INR 130 crore will be split in H2 and FY 2028?
Yeah, it may.
Okay. Thank you.
Thank you. A reminder to all the participants, if you wish to ask a question, you may press star and one. To ask a question, please press star and one now. Anyone who wish to ask a question may press star and one on their touch-tone telephone. Ladies and gentlemen, as there is no question, I would now like to hand the conference over to the management for closing comments. Over to you, sir.
Thank you. Thank you, everybody, for your time, and I hope we have been able to address all your queries. For any further information, kindly get in touch with any one of us or Strategic Growth Advisors or Investor Relations Advisors. I would like to end by wishing everyone a very happy and safe Diwali and a prosperous New Year. Thank you, and have a nice day.
Thank you. On behalf of NOCIL Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.